Navigation Links
$1.5 Million Grant to Yale for Narcolepsy-Neurotransmitter Study

Yale School of Medicine researchers have received a $1.5 million grant from the National Institutes of Health (NIH) to study neurons// that play a major role in narcolepsy.

Narcolepsy is a neurodegenerative disease characterized by daytime sleepiness. The NIH grant will further Yale research into narcolepsy and other disorders linked to neurons that produce the peptide hypocretin.

“The activity of these hypocretin cells is important for enhancing cognitive arousal and resisting sleep, and they may also play a role in anxiety and body weight regulation,” said the principal investigator, Anthony van den Pol, neurosurgery professor.

He said neurons send out long fibers, or axons, to other nerve cells and release either an inhibitor or excitatory neurotransmitter onto their target cells. A small number of these neurons make and secrete the transmitter hypocretin.

Hypocretin neurons actually make two neurotransmitters, hypocretin and dynorphin. The results of Van den Pol’s recent work, published in the Journal of Neuroscience, shows that these two transmitters, or peptides, have actions that oppose each other. Hypocretin increases the excitability of other nerve cells, whereas dynorphin inhibits the activity.

Van den Pol and first author, Ying Li, an associate research scientist, wondered what cellular value opposing neurotransmitters might have. They found that different target neurons in the brain show different responses to co-stimulation by the two peptides.

They came to this finding by using whole cell patch clamp recording, in which an ultra-thin glass pipette, like a very small straw, is used to record the electrical activity caused by movement of ions through channels in single nerve cells.

Van den Pol said that these neurotransmitters had different effects on different cell types. One target, MCH neurons, were excited by hypocretin but inhibited by dynorphin.

“This mi ght suggest that the two neurotransmitters would simply cancel the actions of each other,” van den Pol said. “But, interestingly, in the continuing presence of both neurotransmitters, the inhibitory MCH cell response to dynorphin rapidly declined, whereas the excitatory response to hypocretin persisted.” Therefore, he said, low levels of release of both transmitters might favor inhibition, whereas high levels of release might swing the tide over to excitation and increase cognitive arousal.

However, on another target, NPY neurons, hypocretin directly excited the cells, byt dynorphin had little direct effect. Rather, dynorphin contributed to increased nerve cell activity by reducing the release of inhibitory neurotransmitters onto the NPY cells. In this case, the transmitters act synergistically to excite the NPY cell.

Under the NIH grant, van den Pol and colleagues will study the effects of both naturally occurring neuroactive compounds, as well as man made drugs, to determine how they influence the hypocretin cells, and, ultimately, cognitive arousal.

Source-YALE UniversitySRM
'"/>




Related medicine news :

1. Drug May Make Breathing Easier for Millions
2. Over Six Million HIV Infected People In South Africa- Finds A Survey
3. Tanzanian Government Sanctions $20 Million For AIDS Arug
4. GlaxoSmithKline to Supply United States with 8 Million flu vaccine, Fluarix
5. Number Of Babies Born Prematurely Nears Historic Half Million Mark In US
6. Proper Validation of Generic Drugs Could Save Millions of AIDS Patients
7. An Estimated 150 Million Indians Suffer From Arthritis
8. Acute Shortage Of Neurosurgeons In India: One Surgeon For Every 1 Million!
9. India To Procure 1 Million Doses Of Tamiflu
10. Global Warming Could Cause 5 Million Illnesses: WHO
11. Australia earmarks $74 Million to Fight Bird Flu
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health ... technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing ... form that can be easily incorporated into liquid products, while reducing costs to end ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
Breaking Medicine Technology: